ATE123955T1 - Radiopharmazeutische zusammensetzungen, verabreichungsmethode und verfahren zur herstellung derselben. - Google Patents

Radiopharmazeutische zusammensetzungen, verabreichungsmethode und verfahren zur herstellung derselben.

Info

Publication number
ATE123955T1
ATE123955T1 AT91305485T AT91305485T ATE123955T1 AT E123955 T1 ATE123955 T1 AT E123955T1 AT 91305485 T AT91305485 T AT 91305485T AT 91305485 T AT91305485 T AT 91305485T AT E123955 T1 ATE123955 T1 AT E123955T1
Authority
AT
Austria
Prior art keywords
administration
preparing
same
ligand
frozen
Prior art date
Application number
AT91305485T
Other languages
English (en)
Inventor
Jaime Simon
Joseph R Garlich
R Keith Frank
Kenneth Mcmillan
Original Assignee
Dow Chemical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dow Chemical Co filed Critical Dow Chemical Co
Application granted granted Critical
Publication of ATE123955T1 publication Critical patent/ATE123955T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0489—Phosphates or phosphonates, e.g. bone-seeking phosphonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Developing Agents For Electrophotography (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT91305485T 1990-06-18 1991-06-18 Radiopharmazeutische zusammensetzungen, verabreichungsmethode und verfahren zur herstellung derselben. ATE123955T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US53887190A 1990-06-18 1990-06-18

Publications (1)

Publication Number Publication Date
ATE123955T1 true ATE123955T1 (de) 1995-07-15

Family

ID=24148781

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91305485T ATE123955T1 (de) 1990-06-18 1991-06-18 Radiopharmazeutische zusammensetzungen, verabreichungsmethode und verfahren zur herstellung derselben.

Country Status (32)

Country Link
US (1) US5762907A (de)
EP (1) EP0462787B1 (de)
JP (2) JP3636728B2 (de)
KR (1) KR100219964B1 (de)
CN (1) CN1033143C (de)
AT (1) ATE123955T1 (de)
AU (2) AU651112B2 (de)
BR (2) BR9102579A (de)
CA (1) CA2044812C (de)
CS (1) CS184291A3 (de)
CY (1) CY1891A (de)
DE (1) DE69110554T2 (de)
DK (1) DK0462787T3 (de)
EG (1) EG19862A (de)
ES (1) ES2073678T3 (de)
FI (1) FI101044B (de)
GR (1) GR3017430T3 (de)
HK (1) HK80496A (de)
HU (1) HU226897B1 (de)
IE (1) IE71023B1 (de)
IL (1) IL98536A (de)
IS (1) IS1704B (de)
MC (1) MC2260A1 (de)
NO (1) NO302510B1 (de)
NZ (1) NZ238547A (de)
PH (1) PH30975A (de)
PL (1) PL165699B1 (de)
PT (1) PT97996B (de)
RU (1) RU2095085C1 (de)
SA (1) SA92120343B1 (de)
SK (1) SK279598B6 (de)
ZA (1) ZA914615B (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5410043A (en) * 1991-12-06 1995-04-25 Schering Aktiengesellschaft Process for the production of mono-N-substituted tetraaza macrocycles
US5320829A (en) * 1991-12-10 1994-06-14 The Dow Chemical Company Oral compositions for inhibiting plaque formation
DE4218744C2 (de) * 1992-06-04 1997-11-06 Schering Ag Verfahren zur Herstellung von N-ß-Hxdroxyalkyl-tri-N-carboxylalkyl-1,4,7,10-tetraazacyclododecan- und N-ß-Hydroxyalkyl-tri-N-carboxyalkyl-1,4,8,11-tetraazacyclotetradecan-Derivaten und deren Metallkomplexe
US5405601A (en) * 1993-07-02 1995-04-11 Mallinckrodt Medical Inc. Functionalized tripodal ligands for imaging applications
CN1065769C (zh) * 1997-07-03 2001-05-16 中国原子能科学研究院 一种放射性药物制剂的制备方法
CN1092962C (zh) * 1998-01-26 2002-10-23 贾伟 一种减轻骨及骨关节疾病疼痛的药物
RU2164420C2 (ru) * 1999-02-10 2001-03-27 Государственный научный центр Российской Федерации Физико-энергетический институт им. акад. А.И. Лейпунского Способ получения радиотерапевтического препарата
EP1191948A2 (de) * 1999-06-11 2002-04-03 Neorx Corporation Hochdosierte radionuklide komplexe zur knochenmark-unterdrückung
US7094885B2 (en) * 1999-07-11 2006-08-22 Neorx Corporation Skeletal-targeted radiation to treat bone-associated pathologies
RU2162714C1 (ru) * 2000-06-20 2001-02-10 Государственный научный центр РФ - Институт биофизики Радиофармацевтическая композиция
AU2002249935A1 (en) * 2001-01-08 2002-08-19 Neorx Corporation Radioactively labelled conjugates of phosphonates
RU2205030C2 (ru) * 2001-02-13 2003-05-27 Осминин Александр Георгиевич Средство для рентгенологического исследования
RU2182022C1 (ru) * 2001-05-24 2002-05-10 Российская медицинская академия последипломного образования МЗ РФ Способ лечения онкологических заболеваний щитовидной железы
RU2191033C1 (ru) * 2001-05-24 2002-10-20 Юминов Олег Аркадьевич Радиофармацевтический препарат "астат-211" для лечения онкологических заболеваний щитовидной железы
US6567492B2 (en) 2001-06-11 2003-05-20 Eastern Isotopes, Inc. Process and apparatus for production of F-18 fluoride
US7018614B2 (en) * 2002-11-05 2006-03-28 Eastern Isotopes, Inc. Stabilization of radiopharmaceuticals labeled with 18-F
ATE473019T1 (de) 2002-11-05 2010-07-15 Ion Beam Applic Sa Stabilisierung von wässerigen zusammensetzungen von 18f-markiertem 2-fluoro-2-deoxy-d-glukose mit ethanol
RU2297247C2 (ru) * 2005-06-20 2007-04-20 Государственное учреждение "Институт химии твердого тела" Уральского отделения Российской академии наук Средство для контрастирования при рентгенодиагностике (варианты)
SG11201509042YA (en) * 2013-05-13 2015-12-30 Vision Global Holdings Ltd Pharmaceutical composition comprising modified hemoglobin- based therapeutic agent for cancer targeting treatment and diagnostic imaging
DK3054996T3 (da) 2013-10-07 2023-07-10 Igl Pharma Inc Fremgangsmåde til fremstilling af terapeutiske knoglemidler af høj renhed
WO2016087653A1 (en) 2014-12-04 2016-06-09 Ge Healthcare Limited Method of removing acetaldehyde from radioactive pharmaceuticals
RU2593017C1 (ru) * 2015-04-23 2016-07-27 Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) Способ получения радиофармацевтического препарата "астат-211"
WO2016187514A1 (en) * 2015-05-21 2016-11-24 Actinium Pharmaceueuticals, Inc. Infusion administration of conjugated monoclonal antibodies
US11369700B2 (en) * 2015-05-25 2022-06-28 IGL Pharma Inc. DOTMP kit formulations for radioisotopes
US20180104366A1 (en) * 2015-05-25 2018-04-19 Isotherapeutics Group, Llc Dotmp kit formulations for radioisotopes
RU2757258C1 (ru) * 2020-09-28 2021-10-12 федеральное государственное автономное образовательное учреждение высшего образования "Национальный исследовательский ядерный университет "МИФИ" (НИЯУ МИФИ) Способ получения радиофармацевтического препарата с галлием-68 для визуализации метастазов скелета методом пэт

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4018883A (en) * 1975-03-10 1977-04-19 Nichols Institute For Endocrinology Thyroxine (T4) radioimmunoassay
CA1050425A (en) * 1975-06-26 1979-03-13 Mallinckrodt Radioimmunoassay methods for the determination of l-triiodothyronine and thyroxine
US4301140A (en) * 1979-12-14 1981-11-17 G. D. Searle & Co. Radiopharmaceutical method for monitoring kidneys
US4341755A (en) * 1980-07-15 1982-07-27 Immuno Nuclear Corporation Parathyroid radioimmunoassay
US4457602A (en) * 1981-04-20 1984-07-03 Olympus Optical Company Ltd. Multiple light emission control system utilizing electronic flashes
US4411881A (en) * 1982-07-12 1983-10-25 New England Nuclear Corporation Composition and method for stabilizing radiolabeled compounds using thiocarbonylated diethylenetriamines
IL74902A (en) * 1984-06-04 1990-12-23 Dow Chemical Co Organic amine phosphonic acid complexes with particle-emitting radionuclides for the treatment of calcific tumors
US5059412A (en) * 1984-06-04 1991-10-22 The Dow Chemical Company Macrocyclic aminophosphonic acid complexes for the treatment of calcific tumors
US5064633A (en) * 1984-06-04 1991-11-12 The Dow Chemical Company Macrocyclic aminophosphonic acid complexes, their formulations and use
US4898724A (en) * 1984-06-04 1990-02-06 The Dow Chemical Company Organis amine phosphonic acid complexes for the treatment of calcific tumors
GB8510726D0 (en) * 1985-04-26 1985-06-26 Amersham Int Plc Stabilised radio-labelled compounds
US4752464A (en) * 1985-06-07 1988-06-21 Cadema Medical Products, Inc. Treatment of arthritis, including rheumatoid arthritis, with radioactive isotopes
NZ222304A (en) * 1987-05-18 1990-10-26 Dow Chemical Co Suppression of bone marrow using samarium-153, gadolinium-159 or holmium-166 complexes
US4853209A (en) * 1987-05-18 1989-08-01 The Dow Chemical Company Bone marrow suppressing agents
AU629171B2 (en) * 1987-06-30 1992-10-01 Mallinckrodt, Inc. Method for enhancing the safety of metal-ligand chelates as magnetic resonants imaging agents and x-ray contrast agents
US4937333A (en) * 1989-08-04 1990-06-26 The Dow Chemical Company Method for purifying aminomethylenephosphonic acids for pharmaceutical use
US4882142A (en) * 1988-12-19 1989-11-21 The Dow Chemical Company Bone marrow suppressing agents
US5219556A (en) * 1990-07-09 1993-06-15 Mallinckrodt Medical, Inc. Stabilized therapeutic radiopharmaceutical complexes

Also Published As

Publication number Publication date
EP0462787A1 (de) 1991-12-27
PT97996B (pt) 1998-11-30
CA2044812A1 (en) 1991-12-19
JP2002114712A (ja) 2002-04-16
HK80496A (en) 1996-05-17
HU226897B1 (en) 2010-01-28
KR100219964B1 (ko) 1999-09-01
IS1704B (is) 1998-12-10
HUT57994A (en) 1992-01-28
KR920000334A (ko) 1992-01-29
IE912057A1 (en) 1991-12-18
NO912345D0 (no) 1991-06-17
SK279598B6 (sk) 1999-01-11
BR9102579A (pt) 1992-01-21
DE69110554D1 (de) 1995-07-27
PT97996A (pt) 1992-03-31
CS184291A3 (en) 1992-02-19
CA2044812C (en) 2002-12-31
ES2073678T3 (es) 1995-08-16
AU665911B2 (en) 1996-01-18
JPH04230224A (ja) 1992-08-19
EP0462787B1 (de) 1995-06-21
IL98536A0 (en) 1992-07-15
IE71023B1 (en) 1997-01-15
PH30975A (en) 1997-12-23
CY1891A (en) 1996-08-30
RU2095085C1 (ru) 1997-11-10
PL290717A1 (en) 1992-02-24
IL98536A (en) 1996-10-31
FI912933A0 (fi) 1991-06-17
MC2260A1 (fr) 1993-04-26
IS3717A7 (is) 1991-12-19
SA92120343B1 (ar) 2004-01-25
PL165699B1 (pl) 1995-01-31
FI101044B (fi) 1998-04-15
GR3017430T3 (en) 1995-12-31
FI912933L (fi) 1991-12-19
EG19862A (en) 1996-06-30
ZA914615B (en) 1993-02-24
JP3636728B2 (ja) 2005-04-06
DK0462787T3 (da) 1995-10-30
AU6455994A (en) 1994-08-04
BR1101169A (pt) 2000-08-08
AU651112B2 (en) 1994-07-14
HU912011D0 (en) 1991-12-30
DE69110554T2 (de) 1995-12-14
CN1033143C (zh) 1996-10-30
NZ238547A (en) 1994-05-26
NO302510B1 (no) 1998-03-16
AU7847091A (en) 1991-12-19
US5762907A (en) 1998-06-09
NO912345L (no) 1991-12-19
CN1063615A (zh) 1992-08-19

Similar Documents

Publication Publication Date Title
DE69110554D1 (de) Radiopharmazeutische Zusammensetzungen, Verabreichungsmethode und Verfahren zur Herstellung derselben.
NO883926L (no) Fremgangsmaate for fremstilling av stabilisert humanproteinpreparat.
DE68908125D1 (de) Knochenmark unterdrueckende medikamente.
WO1992000759A3 (en) Stabilized therapeutic radiopharmaceutical complexes
KR910018346A (ko) 킬레이트화 화합물 및 그의 용도
SE7706126L (sv) Radioaktivt preparat
DK0397452T3 (da) Hidtil ukendte præparater
BE886453A (fr) Compositions durcissables par l'oxygene comprenant un mercapto-organosiloxane, un compose fer-carbonyle et un acide
NO883520L (no) Fremgangsmaate for fremstilling av et injeksjonspreparat.
ATE23800T1 (de) Roentgen-sichtbarmachungsmittel.
FR2328453A1 (fr) Peptide marque au 99mtc
EP0127389A3 (en) N,n-diethyl-5-methyl-2h-1-benzothiopyrano-(4,3,2-cd)-indazole-2-ethanamine, compositions comprising the same and uses therefor
OUYANG Efficacy of DMAP Injection in Treatment of HCN Poisoning in Dogs
ATE74770T1 (de) Tc-99m-w-alkylphosphinico-1-hydroxyalkan-1,1diphosphonate enthaltende praeparate zur knochenszintigraphie sowie verfahren zur herstellung dieser praeparate.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee